Global Amyotrophic Lateral Sclerosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Amyotrophic Lateral Sclerosis Treatment Market is presumed to reach the market size of nearly USD 1344.28 Million by 2032 from USD 773.07 Million in 2023 with a CAGR of 6.34% under the study period 2024-2032.

Amyotrophic lateral sclerosis is an accelerating neurodegenerative illness in which nerve cells that regulate voluntary muscles in the central nervous system die. In nearly half of ALS cases, individuals lose the ability to swallow, breathe, speak, walk, and use their hands. Amyotrophic lateral sclerosis is incurable, and no effective treatment can slow or stop its course. Although no treatment can undo the damage caused by amyotrophic lateral sclerosis, it can make people feel more at ease and independent by reducing the progression of symptoms, preventing complications, and improving their overall quality of life. ALS can be treated with physical and occupational therapy, communication assistance, nutritional support, and breathing support.

MARKET DYNAMICS

Adopting a sedentary lifestyle raises the chance of acquiring the disease in the elderly, necessitating the development of new medications and tailored treatment alternatives. These factors are projected to propel the market for amyotrophic lateral sclerosis treatments higher. Growth in the prevalence of amyotrophic lateral sclerosis disease is expected to drive the global amyotrophic lateral sclerosis therapy market. However, the market is expected to be impeded by high treatment costs, a lack of understanding regarding amyotrophic lateral sclerosis disease, and restricted therapy alternatives.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Amyotrophic Lateral Sclerosis Treatment. The growth and trends of Amyotrophic Lateral Sclerosis Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Amyotrophic Lateral Sclerosis Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

Medication
Stem Cell Therapy
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Amyotrophic Lateral Sclerosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Amyotrophic Lateral Sclerosis Treatment market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F.Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, Ionis Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11216729

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS BY TREATMENT

5.1. Overview By Treatment
5.2. Historical and Forecast Data Analysis By Treatment
5.3. Medication Historic and Forecast Sales By Regions
5.4. Stem Cell Therapy Historic and Forecast Sales By Regions
5.5. Others Historic and Forecast Sales By Regions

6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1. Overview By Distribution Channel
6.2. Historical and Forecast Data Analysis By Distribution Channel
6.3. Hospital Pharmacies Historic and Forecast Sales By Regions
6.4. Retail Pharmacies Historic and Forecast Sales By Regions
6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT COMPANIES

8.1. Amyotrophic Lateral Sclerosis Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Mitsubishi Tanabe Pharma Corporation
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Otsuka Pharmaceutical Co. Ltd.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. BrainStorm Therapeutics
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Biogen Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Corestem
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. AB Science
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. F.Hoffmann-La Roche AG
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Biohaven Pharmaceutical
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Sun Pharmaceutical
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Ionis Pharmaceuticals Inc
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies